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Uncontrolled drug pricing in the private healthcare system in Malaysia leads to high drug
prices; however, its impact on employee drug utilization and employer reimbursement
coverage is unclear. This study examined patterns of drug pricing and drug utilization
among employees covered by employer medical insurance. A drug price control
mechanism was also devised for the employer to ensure fair benefits to all parties
without compromising the quality of patient care. This retrospective study was conducted
among International Islamic University Malaysia (IIUM) community members who sought
outpatient treatment at the IIUM panel of health clinics serviced by general practitioners
from January 2016 to September 2019. Prescription data (drug type, dose, quantity,
duration, price, and manufacturer), patient characteristics (age, sex, and diagnosis)
and total charges were extracted from the claims database of PMCare, the insurance
company managing IIUM medical claims. Patterns of commonly prescribed drugs, drug
pricing, profit margins, and total charges per clinic visit were evaluated. Descriptive
statistics were used, and all analyses were performed using Stata v15.1. There were
a total of 161,146 prescriptions for 10,150 patients in the IIUM community during
the study period (48.85% women, mean ± standard deviation; age: 26.33 ± 17.63
years). The most commonly prescribed drug was paracetamol (25.3%), followed
by chlorpheniramine (9.46%), cetirizine (7.3%), diphenhydramine (6.13%), loratadine
(4.57%), and diclofenac (4.36%). Generic paracetamol (500mg), which serves as a prime
example for details on drug pricing, is commonly charged between Ringgit Malaysia (RM)
5 and 10 for 10 tablets with a profit between 2,400 and 4,900% according to the average
cost price of RM 0.20 per 10 tablets. Most patients were charged within the approved
coverage limit of RM 45 per clinic visit, with only 2.41% of patients being charged with
costs that exceeded this limit. Uncontrolled drug pricing in the private healthcare system
in Malaysia indicates that drug prices differ greatly across private healthcare providers
most of the prices were charged with high profit margins. Employers may consider a
multilayer capping system to prevent inappropriate drug pricing, which will inevitably
benefit patients clinically and economically and provide greater patient access to better
drug treatment.
Keywords: drug utilization, uncontrolled drug pricing, employer insurance coverage, price control mechanism,
private healthcare system in Malaysia
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by The International Islamic University Malaysia Repository
Zin et al. Drug Utilization and Drug Pricing
INTRODUCTION
The healthcare system in Malaysia consists of both private and
public sectors. The private sector is a non-subsidized sector that
uses consumers’ out-of-pocket money to pay for the services
(1). This sector is also funded by non-profit institutions, private
institutions, and private health insurance (2). The public sector
is fully funded by the government, where patients receive their
medicines either for free or at a nominal fee. In the private sector,
it is solely free market forces that determine drug pricing, which
results in markups or profit margins for drug prices to be higher
inMalaysia than in other countries (3, 4). The lack of drug pricing
regulations has resulted in healthcare professionals, wholesalers,
and pharmaceutical companies in the private sector to set their
own retail selling price (5, 6).
Private medical clinics in Malaysia usually have services
provided by general practitioners that cater mostly to the self-
paying public that uses fee-for-service methods of payment and
private sector employees. Some private sector employees are
medically covered by their employers through panel clinics or
through insurance arrangements, which have, at times led to high
drug charges primarily because payment is being made by a third
party. This, however, depends on the insurance structure and its
impact on drug prices.
The coverage for International Islamic University Malaysia
(IIUM) employee medical benefits, which include hospitalization
as well as both surgical and outpatient treatment by a general
practitioner (GP), is arranged through an insurance company.
For outpatients, there is a cap of RM 45 (equivalent to USD
10.58 [RM 1 = USD 0.23]) per GP clinic visit. However, IIUM
employees have requested an increase in this coverage to RM 60
(USD 13.59), as the current amount approved is inadequate to
cover the total charges (drug charges and consultation fee) for
each outpatient clinic visit.
The present study aimed to evaluate the patterns of drug
utilization and drug pricing among IIUM community members
seeking treatment at IIUM panel clinics serviced by GPs, and to
devise a price control mechanism for an employer sustainable
reimbursement drug policy. The drugs most commonly used by
the IIUM community, total charges per clinic visit, and profit
margins for drug pricing were examined. In addition, the study
investigated whether the current cap of RM 45 per clinic visit was
adequate to cover employees’ outpatient treatment.
MATERIALS AND METHODS
This study was approved by the IIUM Ethical Committee
(IREC-2019-212). The results of the study are reported in an
aggregated manner using de-identified data. Informed consent
was not required as this study did not involve any direct
patient interaction.
Study Design and Data Source
This retrospective study was conducted in the IIUM community
(employees and dependents) from January 2016 to September
2019, using the claims database from the insurance company
PMCare, which manages and administers medical benefit
programs to various clients. PMCare has about 650,000
members with a network of 2,000 affiliated medical providers in
Malaysia (7).
IIUM is a client of PMCare and pays insurance premiums
to PMCare to provide coverage for medical benefits for their
employees. Given this arrangement, IIUM employees can seek
treatment at any of the private medical clinics from the IIUM
panel that are serviced by PMCare. They are not required to pay
for the service rendered by the clinics if the amount is within the
IIUM-approved coverage of up to RM 45 per clinic visit (USD
10.68), as this amount will be paid by PMCare.
The present study involved outpatient treatment that was
provided by GPs. All IIUM employees (including dependents)
who sought treatment from GPs during the study period
were included. Data on prescriptions (drug type, dose,
quantity, duration, frequency, price for each drug, and drug
manufacturer), patient characteristics (age, sex, and diagnosis),
and total charges (drug charges and consultation fees) were
extracted from the PMCare database. The terms “drug” and
“medication” were used interchangeably in this study. The
term “patients” in this study refers to IIUM employees and
their dependents.
Outcome Measures
Number of Prescriptions, Patients, and Top Six Drugs
Used by the IIUM Community
The total number of prescriptions and patients were assessed, and
the most common drugs or medications prescribed by GPs for
the IIUM community during the study period were identified. GP
consultation fees for each clinic visit were also recorded.
Drug Pricing
Prices charged for each drug in the list of most commonly
prescribed drugs were analyzed, and the manufacturer for each
drug was identified. The price charged by the GPs was then
compared with the cost price given by the manufacturer to
evaluate the profit margin for each drug. Furthermore, the total
cost incurred, using the price charged by the GP, for the top
most commonly prescribed drug was calculated. According to
these analyses, the framework for a drug pricing mechanism was
proposed, and the expected cost saving using this mechanism
was calculated.
Total Charges per Clinic Visit
The total charges (drug charges and consultation fees) per
outpatient clinic visit for each patient were identified. The total
charges per clinic visit per patient that were above the RM-45 cap
were further examined to evaluate the type of drugs used and the
number of drugs prescribed that led to the charges being higher
than the approved amount.
Data Analysis
Descriptive statistics were used to describe patient characteristics,
whereby, the mean and standard deviation (SD) were used
for continuous variables that were normally distributed and
the median and interquartile range (IQR) were used for
continuous variables that were non-normally distributed. Count
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and percentages were used to describe categorical variables. All
statistical analyses were performed using Stata v15.1 (8).
RESULTS
Number of Prescriptions and Patients
A total of 161,146 prescriptions for 10,150 patients (34%
employees and 66% dependents) were identified during the study
period from 2016 to 2019. There were 48.6% women (n =
4,958/10,150) and 51.2% men (n= 5,192/10,150) included in the
study (Table 1). The mean ± SD age of the patients was 26.3 ±
17.6 years, with women (26.3 ± 16.8 years) being slightly older
than men (25.9± 17.4 years).
The most common diagnoses reported by GPs among
the IIUM community seeking treatment were acute upper
respiratory infection (39%), dermatitis and eczema (6.42%),
infectious gastroenteritis and colitis (5.18%), acute tonsillitis
(3.42%), and gastritis (3.01%). The most frequent charges for
the GP consultation fees per outpatient clinic visit were RM 20
(22.49%), followed by RM 15 (21.75%), RM 25 (16.30%), RM 30
(8.96%), RM 10 (8.92%), RM 35 (5.58%), and RM 18 (5.58%).
Drugs Most Commonly Prescribed by GPs
for the IIUM Community
There were ∼1,500 drugs types included in the PMCare
database during the study period. The drug most commonly
prescribed by GPs for the IIUM community was paracetamol
(25.3%), followed by chlorpheniramine (9.46%), cetrizine
(7.3%), diphenhydramine (6.13%), loratadine (4.57%), and
diclofenac (4.36%) (Figure 1). Most of these drug products were
generic brands.
Paracetamol was at the top of the list (n = 26,922, 25.26%)
of the most commonly prescribed drugs. For paracetamol, there
were different formulations with varying strengths, including
500-mg paracetamol tablets, 650-mg paracetamol tablets, 250-
mg/5-mL paracetamol suspension, and a combination tablet
containing 35-mg orphenadrine citrate and 450-mg paracetamol.
Of these, the 500-mg paracetamol tablet (n = 9,133, 62.4%)
was the most frequently prescribed (Figure 2). This product was
further used as an example for the evaluation of drug pricing.
Drug Pricing
Of the generic branded paracetamol 500mg tablets prescribed,
62% (n = 5,687) were supplied by Duopharma Sdn Bhd. From
this manufacturer, 35% (n = 2,013) of the paracetamol 500mg
tablets were dispensed as blister packs of 10 tablets. These blister
packs were charged differently by the GPs, with prices ranging
from RM 2 to RM 20. The most commonly charged price for this
product was RM 5 (41.13%), followed by RM 10 (21.61%), RM 6
(14.65%), RM 4 (6.46%), RM 7 (4.87%), RM 8 (4.62%), and other
prices (6.66%) (Figure 1).
The cost price for generic paracetamol 500mg from
Duopharma Sdn Bhd was RM 0.20 per 10 tablets (cost price at the
time this study was conducted). If these 10 paracetamol tablets
are charged at RM 5 (USD 1.19), it would result in a profit margin
of ∼2,400%, and if they are charged at RM 10 (USD 2.37), it
would result in a profit margin of 4,900%, which is exceedingly
TABLE 1 | Patient demographics.









Range 1 to 78
SD 17.1
Age group (years old)
0 to 9 2,002 20.65
10 to 19 2,272 23.44
20 to 29 1,401 14.45
30 to 39 1,504 15.51
40 to 49 1,375 14.18
50 to 59 898 9.26
≥60 242 2.50







Most common diagnoses (≥2%)
Acute Upper Respiratory Infection, Unspecified 39,716 39.28
Dermatitis And Eczema 6,488 6.42
Infectious Gastroenteritis And Colitis 5,240 5.18
Acute Tonsillitis, Unspecified 3,457 3.42
Gastritis, Unspecified 3,046 3.01
Other And Unspecified Asthma 2,887 2.86
Essential (Primary) Hypertension 2,399 2.37
Other Specified Headache Syndromes 2,286 2.26
Unspecified Conjunctivitis 2,254 2.23
Age among 9,694 patients, 456 patients with missing age.
Amoxicillin (antibiotics) has 4,661 prescriptions (4.37%). All other drugs were
prescribed <4%.
All other diagnoses were <2%.
high and does not adhere to the recommended selling price that
ranges from RM 1 (USD 0.23) to RM 4 (USD 0.95) per blister
pack of 10 tablets.
Given the variation in the prices charged, the total expense for
all paracetamol 500mg packs of 10 tablets (n = 2,013) supplied
by Duopharma Sdn Bhd during the study period was RM 12,926
(USD 3,067.76). If the price for this generic brand of paracetamol
500mg is capped at RM 5 per 10 tablets, the total expense for
this product would be RM 9,735 (USD 2,310.43), and if capped
at RM 4, the total expense would be RM 7,941 (USD 1,884.66).
This would result in an expected cost saving of ∼24.7% with the
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FIGURE 1 | Top six medications prescribed for IIUM community and prices for paracetamol 500mg 10 tablets from Duopharma Sdn Bhd.
proposed RM 5 cap, and an expected cost saving of ∼38.6% with
the proposed RM 4 cap (Figure 3).
Other commonly prescribed drug products, such as
chlorpheniramine tablets, cetirizine tablets, diclofenac sodium
tablets, diphenhydramine syrup, and loratadine tablets, were
also mainly charged at RM 10 per 10 tablets or per bottle (for
diphenhydramine syrup). The cost for these generic drugs
ranged from RM 0.37 to RM 1.10 for 10 tablets, indicating a
profit margin ranging from ∼809 to 2,602%, which is similar to
that of the paracetamol product. For diphenhydramine syrup,
the cost is RM 6 per bottle, indicating a profit margin of 66.6%
(Table 2).
Total Charges for Outpatient Clinic Visits
The amount charged by the GPs for treating members of the
IIUM community ranged from RM 25 to more than RM 100
per clinic visit. The most common range of amounts charged per
clinic visit was >RM 35 to ≤RM 45 (77.6%), followed by >RM
25 to ≤RM 35 (11.9%), ≤RM 25 (8%), and >RM 45 (2.41%)
(Figure 4).
Patients with charges exceeding the IIUM-approved coverage
of RM 45 per clinic visit were mainly prescribed branded drugs
such as gliclazide (Diamicron R©) for diabetes and irbesartan
(CoAprovel R©) for hypertension. Most of these patients were
only prescribed one (42.47%) of these branded drugs for a short
duration of treatment, and this exceeded the approved coverage
amount of RM 45 per clinic visit.
Patients prescribed with two drugs, where their total charges
exceeded the approved coverage of RM 45 per clinic visit, were
usually prescribed with commonly used drugs such as generic
paracetamol and cetirizine for minor cough and cold conditions.
The amount exceeding RM 45 was because of the charge of≥RM
10 for each drug, making the drug charge approximately RM 20
for the two products. Along with consultation fees, this charge
would exceed RM 45 per clinic visit.
For patients prescribed with three or more drugs, where the
total charges exceeded RM 45 per clinic visit, it was observed
that antibiotics such as cephalexin and erythromycin were
often prescribed along with the commonly used drugs such as
paracetamol and cetirizine. The prices for antibiotics ranged from
RM 10 to RM 30 for a 5- to 7-day course; thus, the total charge
per clinic visit would exceed RM 45.
DISCUSSION
This study showed that uncontrolled drug pricing in the private
healthcare system in Malaysia has resulted in varying ranges of
drug prices among GPs at private medical clinics. The high profit
not only costs a lot to the employers but also to the patients
who have to pay out-of-pocket for the drugs. This suggests that
mechanisms should be developed to ensure accessibility and
affordability and to provide fair benefits to all parties without
compromising the quality of patient care (9, 10).
There are several price control mechanisms commonly used
to decrease drug cost expenditure by the government, including
reference pricing (internal and external), tiered formularies,
and price caps (11–13). Internal reference pricing uses price
comparisons across equivalent drugs within the same country,
and external reference pricing uses price comparisons of similar
drugs in one country with those in another country or in a group
of countries (14). If higher-cost drugs are prescribed, patients pay
the difference. For tiered formularies, patients face incrementally
higher copayments for different treatment options, for example,
low copayments with first-tier drugs within a class and higher
copayments for second- and third-tier drugs within a class (15).
With regard to price caps, some countries set price caps on
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FIGURE 2 | Cohort flow chart for paracetamol analysis.
generic drugs and/or regulate the maximum reimbursement rate
to limit pharmaceutical companies from charging high prices
(16–18). Malaysia is just beginning the planning of its drug
price control mechanism, which still requires additional time and
stages before it can be implemented. The findings from this study
can form the preliminary groundwork for developing the price
control mechanism.
Using paracetamol as a prime example in evaluating drug
pricing details, the present study showed that capping the price
for this generic drug at RM 4 or at RM 5 per 10 tablets would
result in cost savings of ∼25 to 40% for the employer. If the
current expenditure for drug reimbursement is ∼1 million per
year, using this example, IIUM could save between RM 250,000
and RM 400,000 per year. The capping system could also be
extended to the price of other commonly used drugs for an even
greater cost savings. The recommended capping of prices would
still allow GPs to have profit margins between 1,900 and 2,400%.
Therefore, all parties (patients, employers, and GPs) would still
benefit from the system, which would be a win-win outcome.
While these commonly used drugs are mainly used for acute
minor illnesses, the proposed capping system will not include
drugs prescribed for chronic illnesses, and this may limit the
treatment options with the proposed system (11).
For chronic illnesses, prescribing of low-cost generic drugs
that have similar therapeutic activity should be promoted.
These products have similar efficacy profiles to originators or
branded drugs; thus, patient care will not be undermined,
and substantial saving can be achieved (19–21), as well as
improved prescribing efficiency (22, 23). Several initiatives have
been introduced to enhance the generic prescribing in Western
European Countries, such as demand-side measures (24) which
include educational activities, prescribing targets, prescribing
restrictions, compulsory International Nonproprietary Name
(INN) prescribing and financial incentives for patient co-
payment differentials (20, 21). Malaysia should learn from these
measures and choose the most effective measure to manage its
pharmaceutical cost.
The needs for prescribing of low-cost generic drugs was also
shown in the current study in which, with only one expensive
branded drug, total charges have already exceeded the approved
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FIGURE 3 | Drug expenses with the current pricing system and expected cost saving with the proposed capping system for generic paracetamol 500mg 10 tablets.
TABLE 2 | List of most common drugs, costs and profit margins.
Name of drug Manufacturer Amount Cost price Selling price Profit margin
Chlorpheniramine tablet Sunward 10 s 0.37 RM 10 2,602%
Diphenhydramine syrup Xepa- Soul Pattinson 120ml 6.00/bottle RM 10 66.6%
Diclofenac sodium 50mg tablet YSP 10 s 0.97 RM 10 930%
Loratadine tablet Pharmaniaga 10 s 0.90 RM 10 1,011%
Cetirizine tablet Xepa-Soul 10 s 1.10 RM 10 809%
The cost price was from the manufacturer supplying a particular drug.
The selling price was based on the most common selling price for a particular drug.
10s, 10 tablets; RM, Ringgit Malaysia.
FIGURE 4 | Total charges per clinic visit and number of drugs prescribed for total charges >RM 45.
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FIGURE 5 | Framework for multilayer capping system.
coverage of RM 45 per clinic visit. If low-cost generic drugs were
prescribed, the approved amount would allow patients to receive
more than one drug for their illnesses. Information about generic
and branded drugs need to be conveyed to patients. If they
prefer the branded drug, then they pay the difference. Concerning
the small percentage of patients (2.41%) exceeded RM 45 per
clinic visit shown in the present study, it may be because of the
unrecorded out-of-pocket payments made by the patients. This
may underestimate the real number of patients exceeding the
coverage amount. Thus, GPs are required to report the exact
details of what was done in practice.
Patients may benefit from the proposed capping system with
regard to the number of medications they can access per clinic
visit. Prior to capping, they may receive only two types of
medications with the approved coverage of RM45 per visit (∼RM
20 for two medications and the balance for consultation fees).
With the capping system, they may be able to receive three to
four types of medications per visit (RM 5 for each medication for
a total charge for three to four drugs of ∼RM 20 and the balance
for consultation fees). Although the consultation fees may vary
depending on the complexity of cases, the current study showed
that RM 20 (range: RM 10 to RM 35) was the most commonly
charged consultation fee. This can accommodate the coverage
amount of RM 45 per clinic visit for drug charges as well as
consultation fees.
The proposed capping of individual drug pricing in this study
will be in addition to capping the total approved amount covered
of up to RM 45 per clinic visit (Figure 5). This multilayer capping
system will prevent inappropriate drug pricing, and improve
patient surplus and social welfare (25). Without any control on
drug pricing, the current approved coverage (RM 45 per visit) or
the revised coverage (RM 60 per visit as requested by employees)
will not make a significant difference to the current situation, as
the price of drugs and consultation fees can be manipulated to
the maximum allowable coverage during every clinic visit.
Other measures are also required to facilitate the multilayer
capping system, including regular monitoring of the pattern
of drug use by the employees. Data on patient claims at
the individual level need to be obtained from the insurance
company for monitoring purposes. Also, GPs are required to
provide details on individual drug charges and consultation
fees. These detailed charges have already been in practice at
private tertiary hospital settings in Malaysia, but they are still
lacking in private primary care settings. Employers need to
emphasize this before renewing the appointment of panel clinics.
At the national level, efforts to contain drug pricing in the
private sector may be conducted using several different methods
including a database with transparent drug pricing that requires
disclosure of the recommended retail price by the manufacturer
or wholesaler, and is made available for public access (26). In
addition, public announcements and emphasis on drug price
transparency can also provide options that are both effective and
efficient for consumers in their procurement, and which in the
long term would lead to healthy competition that may decrease
medicine prices and increase consumer access to affordable
medicines (27).
Apart from the above measure of price capping and
prescribing of low-cost generic drugs in an effort to contain
the pharmaceutical cost, the employer or the payer may
also consider the drug formulary that lists of all essential
medicines/well accepted drugs for private primary care setting.
While this list is available within the public health system in
Malaysia, it is lacking within the private health sector. The
list provides high quality evidence based recommendations
to prescriber which is in line with the recommendation of
the Lancet’s Commission on Essential Medicines policies to
achieve Sustainable Development Goal 3.8 on universal access
to safe, effective, quality and affordable essential medicines and
vaccines (28). Concerning the private primary care setting,
the range of medicines can be smaller than the range in
tertiary care settings, because primary care typically deals
with simple clinical cases and complicated cases are referred
to tertiary settings. Nevertheless, the “Wise List” of essential
medicines in Sweden is applicable for both primary and
specialized care in Stockholm Healthcare Region and this
list has gained strong acceptance and high adherence among
prescribers (29).
This study provides important information on the patterns
of drug use and drug pricing among private medical clinics,
which can serve as paramount evidence in strategizing
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the price control and reimbursement drug policy. For the
private primary healthcare system in Malaysia, this provides
the groundwork for them to move forward in tackling
the issue of high drug cost and uncontrolled drug pricing
in the private sector. A number of limitations to this
study need to be acknowledged, including the database
accessed for this study that may have only captured the
total charges within the maximum allowable coverage (≤
RM 45) for reimbursement from the insurance company,
thus underestimating the actual number of patients who
may have exceeded the maximum coverage amount. There is
also a possibility that drugs prescribed within the exceeded
coverage were not captured in the database. However, data
in this study from a small number of patients who had
exceeded the maximum coverage amount provide some basic
information on patterns of drug use and drug pricing among
this group, making the results of study beneficial in providing
information for the future. Further, this study included data
primarily from private GPs, which limits its generalization
to other healthcare providers or settings such as private
community pharmacies.
CONCLUSION
Uncontrolled drug pricing in the private healthcare system
in Malaysia indicates that drug prices differ greatly across
healthcare providers at private medical clinics, primarily those
with high profitmargins. Themultilayer capping system covering
total claim amounts and selected individual drug charges will
prevent inappropriate drug pricing in the private sector, and
this will inevitably benefit patients clinically and economically,
as patient accessibility to better drug treatment will become
possible. Prescribing of generic drugs should be promoted
and a drug formulary for primary care setting should also be
considered to further improve cost containment and prescribing
efficiency. The current maximum allowable coverage for the
IIUM community at RM 45 per clinic visit may need to be
revised when further evidence is available for justification. IIUM
can be the first in implementing its own drug price control
mechanism at the institutional level to ensure rational drug use
among its employees, and at the same time, ensure financially
sustainable reimbursement drug policy for IIUM. This could
become a blueprint for other employers as well as lay the
groundwork for the country in setting a national drug price
control mechanism.
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